Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study
Authors' conclusion
Higher BMI mediated more than half of the diabetogenic effects of statins, which did not extend to other commonly used lipid modifiers. Further investigations are needed to clarify drug-specific mechanisms underlying the effects of lipid modifiers on type 2 diabetes.
Study context
- Population
- People of European ancestry and, where possible, East Asians in genome-wide association studies (GWAS)
- Comparison
- Genetically mimicked statins, PCSK9 inhibitors and ezetimibe
- Outcome
- T2D risk
Methodological detailsgenetic variants mimicking lipid modifiers, largest relevant GWAS, European ancestry and, where possible, East Asians
- Genetic variants mimicking lipid modifiers
- Largest relevant GWAS
- European ancestry and, where possible, East Asians
Main finding
As reported in the abstract
T2D risk per SD reduction in LDL-C
| Group | Value | OR |
|---|---|---|
| Statins | 1.74 (95% CI 1.49–2.03) | 1.74 |
| Ezetimibe | 1.92 (CI 1.22–3.02) | 1.92 |
| PCSK9 inhibitors | 1.06 (CI 0.87–1.29) | 1.06 |
Value
Statins1.74 (95% CI 1.49–2.03)
Ezetimibe1.92 (CI 1.22–3.02)
PCSK9 inhibitors1.06 (CI 0.87–1.29)
OR
Statins1.74
Ezetimibe1.92
PCSK9 inhibitors1.06
Further findings
- Body mass index (BMI) per SD reduction in LDL-C — Statins
- 0.33 (CI 0.29–0.38) SD
- BMI per SD reduction in LDL-C — Share of statin effect on T2D risk explained by BMI
- 54%
BMI per SD reduction in LDL-C
- Only statin mimics associated with higher BMI
Original publication
Statins, Type 2 Diabetes, and Body Mass Index: A Univariable and Multivariable Mendelian Randomization Study. J Clin Endocrinol Metab. Published 3 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →